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Background 
There are no longitudinal data on the changes in hematologic, hepatic, and renal function findings in 
patients with Middle East respiratory syndrome coronavirus (MERS‐CoV) infection. 
Methods 
This is a retrospective cohort study of 16 MERS‐CoV patients, to describe the hematological, hepatic, 
and renal findings of patients with MERS‐CoV. 
Results 
During the 21 days of observation, there was no significant change in the hepatic panel or creatinine 
tests. There was a significant increase in the mean ± SD of the white blood cell count from 8.3 ± 4.6 to 
14.53 ± 7 (P value = 0.001) and an increase in mean ± SD of the absolute neutrophil count from 6.33 ± 
4.2 to 12 ± 5.5 (P value = 0.015). Leukocytosis was observed in 31% (5/16) of the patients on day 1 and 
in 80% (4/5) on day 21. Transient leukopenia developed in 6% (1/16) of the patients on day 1 and in 13% 
(1/8) on day 8. None of the patients had neutropenia. Lymphopenia was a prominent feature with a rate 
of 44% (7/16) of the patients on day 1 and 60% (3/5) on day 21. Lymphocytosis was not a feature of 
MERS‐CoV infection. Thrombocytopenia developed in 31% (5/16) of the patients on day 1 and 40% (2/5) 
on day 21. Thrombocytosis was not a prominent feature and was observed in 6% (1/16) of the patients 
on day 1 and 17% (1/6) on day 9. 
Conclusions 
Patients with MERS‐CoV infection showed variable hematologic parameters over time. Lymphocytosis 
and neutropenia were not features of MERS‐CoV infection. 
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Introduction 
The Middle East respiratory syndrome coronavirus (MERS‐CoV) infection was first reported in Saudi 
Arabia in 2012 [1]. The World Health Organization (WHO) had reported as of July 6, 2016 a total of 1782 
cases including 634 deaths in 26 countries worldwide [2]. MERS‐CoV infection was associated with a 
high case fatality rate (CFR) and subsequently the CFR decreased as more patients had a milder form of 
the disease 3. Although many studies evaluated the clinical characteristics of MERS‐CoV patients, none 
of them addressed the temporal changes in hematologic, hepatic or creatinine values [4‐7]. Acute renal 
injury was described in 92% of critically ill patients 5. However, many MERS patients had preexisting 
chronic renal disease [4, 8, 9]. In this study, we evaluated the temporal progression and changes in 
hematologic, hepatic, and renal function in a cohort of patients over 21 days of hospitalization. 
Methods 
In this study, we analyzed hematologic, hepatic, and creatinine changes over time in a cohort of 16 
admitted patients with MERS‐CoV infection. All patients tested positive for MERS‐CoV using real‐time 
polymerase chain reaction (RT‐PCR) [4]. Day one is the first day of admission, and subsequent days after 
admission were based on this calculation. Laboratory data were collected for 21 days after admission. 
This time limit was determined based on the fact that most patients were discharged or were deceased 
after the defined time interval. 
The definition of leukopenia was a leukocyte count <4.0 × 109 cells/L, lymphopenia as a lymphocyte 
count <1.0 × 109 cells/L, thrombocytopenia as a platelet count <150 × 109 cells/L, and elevations of 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were defined as twice the 
upper reference limit (34 and 55 U/L, respectively) [5]. Elevated lactate dehydrogenase (LDH) was 
considered as a value significantly elevated above the upper normal level of 280 U/L for the purposes of 
this study. 
We collected daily laboratory data and calculated the mean ± standard deviation (SD) for any given 
parameter. We also calculated the number and percentage of patients who had abnormal laboratory 
data as defined below. The study was approved by the Institution Review Board (IRB) of Johns Hopkins 
Aramco Healthcare. 
Statistical analysis 
The Kendall–Mann test was obtained using SPSS (SPSS for Windows, version 11; SPSS Inc., Chicago, IL, 
USA; 2002) for the time trend of the individual patient to test for a monotonic trend of the different 
laboratory variables. To compare the mean of the laboratory values of all patients over time, we used 
paired t‐test for analysis of variance (anova) test using spss (SPSS for Windows, version 11; SPSS Inc.). In 
each test, a significant result was considered present when the P value was <0.05. 
Results 
The serum creatinine for individual patients did not show a significant trend over time using the 
Kendall–Mann test, except for three patients. The baseline mean serum creatinine ± SD was 4.1 (± 4.2) 
mg/dL indicating the presence of renal impairment prior to admission in those patients (Table 1). 
However, the mean serum creatinine of all patients did not change over time. 
 
Table 1. Creatinine changes over 21 days 
Day Number of patients Mean SD 
1 16 4.1 4.2 
2 11 4.1 3.7 
3 14 3.1 2.7 
4 11 3.7 3.4 
5 10 4.2 3.8 
6 11 4.7 4.2 
7 7 5.9 4.1 
8 8 5.4 4.7 
9 6 3.4 2.8 
10 8 2.3 2.2 
12 9 2.6 2.1 
14 10 2.5 2.0 
17 6 2.3 1.5 
21 5 3.8 2.1 
The hepatic function test results for individual patients did not show a significant trend over time using 
the Kendall–Mann test. The mean ± SD of alkaline phosphatase was 101 ± 34.3 U/L; AST 43.1 ± 25.9 U/L; 
and LDH 847.7 ± 462.4 U/L. There was no significant change in mean hepatic function tests for all 
patients over the study period (Table 2). However, there was an increase in these tests at day 21 due to 
a single patient who developed shock liver. 


















1 10 101 34.3 43.1 25.9 56.0 40.9 847.7 462.4 1 10 0 
2 6 114.5 102.3 37.5 7.2 53.5 8.4 728.7 217 4 11.3 2.2 
3 4 138 107.5 52.5 29.6 70.8 41.5 959 508 1 14 0 
4 3 165.3 147.8 41.3 24.6 70.3 58.5 858.7 522.4 1 12 0 
5 2 54.5 27.6 28.5 0.7 22.0 8.5 730.5 111 11 2.7 6.1 
6 2 105 22.6 141 163 310.5 422.1 578 43.8 2 19 2.8 
8 1 35 0 22 0 22.0 0 802 0 1 7 0 
9 1 40 0 23 0 24.0 0 947 0 1 0.5 0.1 
10 2 59 25.5 34.5 17.7 55.5 43.1 1112 14.1 6 21 0 
12 2 53 15.6 37 25.5 40.5 29 836.5 20.5 1 0.5 0.2 
14 3 64 12.1 37 12.5 47.0 35.2 1029.7 262.7 1 6 0 
17 1 165 0 36 0 92.0 0 2360 0 3 10.6 3.7 
21 4 257.3 160.8 476 793 661.0 1214.3 1825.8 1544 
During the 21 days of observation, three patients had a significant increase in white blood cell (WBC) 
count using the Kendall–Mann test (P = 0.04). There was a significant increase in the mean ± SD of the 
WBC count from 8.3 ± 4.6 to 14.5 ± 7 × 109 cells/L (P value = 0.001) (Figure 1). Leukocytosis was 
observed in 31% (5/16) of patients on day 1 and in 80% (4/5) on day 21. Transient leukopenia developed 
in 6% (1/16) of the patients on day 1 and in 13% (1/8) on day 8. None of the patients had leukopenia 
after day 8 (Table 3). 
Figure 1 
An error bar indicating the mean Â± standard deviation of daily white blood cell count (Ã—109/L). 
Number of White blood cell count, n (%) Platelet count, n (%) Absolute neutrophil count, n (%) Absolute lymphocyte count, n (%) 
Days Patients Leukopenia Leukocytosis Thrombocytopenia Thrombocytosis Neutrophilia Neutropenia Lymphopenia Lymphocytosis 
1 16 1 (6) 5 (31) 5 (31) 1 (6) 1 (6) 0 (0) 7 (44) 0 (0) 
2 11 2 (18) 1 (9) 3 (27) 1 (9) 1 (9) 0 (0) 6 (55) 0 (0) 
3 13 2 (15) 2 (15) 3 (23) 1 (8) 1 (8) 0 (0) 7 (54) 0 (0) 
4 12 1 (8) 3 (25) 2 (17) 1 (8) 2 (17) 0 (0) 6 (50) 0 (0) 
5 11 1 (9) 3 (27) 1 (9) 1 (9) 1 (9) 0 (0) 5 (45) 1 (9) 
6 11 1 (9) 4 (36) 1 (9) 1 (9) 1 (9) 0 (0) 6 (55) 1 (9) 
7 7 1 (14) 3 (43) 0 (0) 1 (14) 2 (29) 0 (0) 5 (71) 0 (0) 
8 8 1 (13) 5 (63) 0 (0) 1 (13) 2 (25) 0 (0) 5 (63) 0 (0) 
9 6 0 (0) 3 (50) 0 (0) 1 (17) 1 (17) 0 (0) 3 (50) 0 (0) 
10 8 0 (0) 3 (38) 1 (13) 1 (13) 1 (13) 0 (0) 4 (50) 0 (0) 
12 10 0 (0) 6 (60) 1 (10) 1 (10) 0 (0) 0 (0) 7 (70) 0 (0) 
14 8 0 (0) 5 (63) 2 (25) 0 (0) 4 (50) 0 (0) 6 (75) 1 (9) 
17 6 0 (0) 4 (67) 1 (17) 0 (0) 4 (67) 0 (0) 4 (67) 0 (0) 
21 5 0 (0) 4 (80) 2 (40) 0 (0) 2 (40) 0 (0) 3 (60) 0 (0) 
Table 3. Number and percentage of patients with specified hematologic changes over time in patients with Middle East respiratory syndrome coronavirus infection
There was a significant increase in the mean ± SD of the absolute neutrophil count from 6.3 ± 4.2 to 12 ± 
5.5 × 109 cells/L (P value = 0.015) (Figure 2), and five patients had a significant correlation of the trend of 
absolute neutrophil count over time (P value = 0.02; Kendall–Mann test). Over the course of the 
observation, neutrophilia was observed in 6% (1/16) of the patients on day 1 and in 25% (2/8) on day 8. 
None of the patients had neutropenia during the hospitalization. 
Figure 2   An error bar indicating the mean ± standard deviation indicating daily absolute neutrophil 
(PMN) count (×109/L). 
The mean ± SD of the absolute lymphocyte count showed no significant change over time for the entire 
group of patients (P = 0.78) (Figure 3). Three patients had a significant correlation in the trend of 
lymphocyte count over time (P value = 0.01; Kendall–Mann test). Over the study period, lymphopenia 
was a prominent feature with a rate of 44% (7/16) of the patients on day 1 and 60% (3/5) on day 21. 
Lymphocytosis was not a feature of MERS‐CoV infection (Table 3). 
Figure 3. An error bar indicating the mean ± standard deviation indicating daily absolute lymphocyte 
count (×109/L).  
The mean ± SD of platelet count showed no significant change over time for the whole group of patients 
(P = 0.49) (Figure 4). Nine patients had a significant correlation in the trend of platelet count over time 
(P value < 0.05; Kendall–Mann test). Thrombocytopenia developed in 31% (5/16) of the patients on day 
1 and 40% (2/5) on day 21. Thrombocytosis was not a prominent feature and was observed in 6% (1/16) 
of the patients on day 1 and 17% (1/6) on day 9. 
Figure 4.  An error bar indicating the mean ± standard deviation indicating daily platelet count (×109/L). 
Discussion 
In this study, we evaluated longitudinal trends of laboratory parameters in patients with MERS‐CoV 
infection. Acute kidney injury is one of the complications or preexisting conditions of MERS‐CoV 
infection. The initially described hospital outbreak occurred in a hemodialysis unit among patients with 
chronic renal failure [8]. Similarly, the majority of the patients in this cohort had preexisting renal 
insufficiency. In a cohort of intensive care unit (ICU) patients, renal replacement therapy was initiated in 
58% of patients compared with 5% of severe acute respiratory syndrome (SARS) patients [5]. Acute renal 
injury may be caused directly by MERS‐CoV as summarized in 12 cases [10]. Renal epithelial cells were 
more likely to produce infectious MERS‐CoV progeny than bronchial epithelial cells [10]. However, 
MERS‐CoV was detected infrequently in urine [11]. 
Lymphopenia was a prominent feature with a rate of 44–60%, and lymphocytosis was not a feature of 
MERS‐CoV infection. It was stated that patients with MERS‐CoV infection typically have 
lymphopenia [1, 4, 8, 9, 12‐14]. Of ICU patients with MERS‐CoV infection, nine of 12 patients (75%) had 
lymphopenia on day 1, and 11 (92%) during the ICU stay [5]. In one study of 47 cases, lymphopenia was 
an initial feature of 34% compared with lymphocytosis in 11% [9]. However, lymphopenia was not a 
feature of the disease when comparing MERS‐CoV patients and those without MERS [4]. Previously 
reported lymphocyte count ranges were as follows: 1.55 [4], 0.9 (range 0.3–2.7) [5], 0.9 (range 0.6–
1.2) [7], 0.9 (range 0.5–6.9) [6]. 
It was reported that 91% of 47 MERS‐CoV cases had normal neutrophil counts on admission [9]. The 
current study showed a normal neutrophil count with a significant increase in the mean (±SD) count 
over time. In a case–control study, there was no difference in neutrophil count between MERS cases and 
other patients with community acquired respiratory infection [4]. In the current study, transient 
leukopenia developed in 9–18% of the patients until day 8 of observation, and 9–80% of the patients 
had leukocytosis until day 21. The increase in the WBC count over time is probably a reflection of the 
development of sepsis or superimposed bacterial infections. 
Thrombocytopenia developed in 31% of patients on day 1 and 40% of patients on day 21 and 
thrombocytosis was not a prominent feature in the current study. Variable degrees of 
thrombocytopenia were inconsistently reported in previous studies [15]. In critically ill ICU MERS‐CoV 
patients, thrombocytopenia was noted in two patients on day 1 and in seven patients (58%) during the 
ICU stay [5]. In the first reported hospital outbreak in Al‐Hasa, four patients had low platelet counts (110 
× 109/L to 122 × 109/L) and only one patient had a high platelet count (468 × 109/L) [8]. In a study of 47 
MERS‐CoV cases, thrombocytopenia developed initially in 36% of cases [9]. Thrombocytopenia is a 
nonspecific finding in many viral infections such as SARS [16, 17]. In SARS cases, thrombocytopenia 
developed initially and was then followed by reactive thrombocytosis [16]. Reactive thrombocytosis was 
only seen in 6–17% of the patients in the current study. 
Elevated levels of LDH, AST, and ALT were found in 49%, 15–53%, and 11–18% of patients with MERS‐
CoV [4, 8, 9]. We observed no significant trend over time in hepatic panels. There was a general 
elevation in LDH from the first day of observation with no significant increase over time. In comparison, 
patients with SARS showed elevation of LDH in 50–70% of cases [18‐20]. Elevated LDH could be a marker 
of severe pneumonia and was associated with death in patients with Legionella pneumophilia [21]. LDH 
is also a surrogate marker for steroid therapy in pediatric Mycoplasma pneumoniae pneumonia [22] and 
it is a predictor of refractory M. pneumoniae pneumonia [23]. To our knowledge, LDH was not examined 
systematically in admitted patients with MERS‐CoV infection. Although more MERS‐CoV patients had 
elevated LDH (47%) vs. other causes of pneumonia (29%), the difference was not statistically 
different [4]. The utility of this marker for the prediction of MERS‐CoV pneumonia progression and 
therapy requires further studies. 
In conclusion, MERS‐CoV infection was associated with variable hematologic parameters over time 
including significant leukocytosis and neutrophilia. Lymphocytosis and neutropenia were not common 
features of MERS‐CoV infection. The utility of LDH as a marker for the prediction of MERS‐CoV 
pneumonia progression and therapy requires further studies. 
Funding 
None of the authors have received funding for their contributions. 
Conflict of Interest 
The authors declare no conflict of interest. 
References 
1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel
coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367: 1814– 20.
2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS‐CoV) ‐ Saudi
Arabia. Disease outbreak news, 6 July 2016. Available at: http://www.who.int/csr/don/06‐july‐2016‐
mers‐saudiarabia/en/. Accessed October 10, 2016.
3. Al‐Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus: transmission and
phylogenetic evolution. Trends Microbiol 2014; 22: 573– 9.
4. Al‐Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A, Memish ZA. Middle East
Respiratory Syndrome‐Coronavirus (MERS‐CoV): a case–control study of hospitalized patients. Clin
Infect Dis 2014; 59: 160– 5.
5. Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, Hawa H, Alothman A, Khaldi
A, Al Raiy B. Clinical course and outcomes of critically ill patients with Middle East respiratory
syndrome coronavirus infection. Ann Intern Med 2014; 160: 389– 97.
6. Shalhoub S, Farahat F, Al‐Jiffri A, Simhairi R, Shamma O, Siddiqi N, Mushtaq A. IFN‐α2a or IFN‐β1a
in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a
retrospective study. J Antimicrob Chemother 2015; 70: 2129– 32.
7. Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, Selim MA, Al Mutairi M, Al Nakhli D, Al
Aidaroos AY, Al Sherbeeni N, Al‐Khashan HI, Memish ZA, Albarrak AM. Clinical aspects and outcomes
of 70 patients with Middle East respiratory syndrome coronavirus infection: a single‐center
experience in Saudi Arabia. Int J Infect Dis 2014; 29: 301– 6.
8. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad
M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al‐Tawfiq JA, Cotten M, Watson SJ, Kellam
P, Zumla AI, Memish ZA, KSA MERS‐CoV Investigation Team. Hospital outbreak of Middle East
respiratory syndrome coronavirus. N Engl J Med 2013; 369: 407– 16.
9. Assiri A, Al‐Tawfiq JA, Al‐Rabeeah AA, Al‐Rabiah FA, Al‐Hajjar S, Al‐Barrak A, Flemban H, Al‐Nassir
WN, Balkhy HH, Al‐Hakeem RF, Makhdoom HQ, Zumla AI, Memish ZA. Epidemiological,
demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome
coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13: 752– 61.
10. Eckerle I, Müller MA, Kallies S, Gotthardt DN, Drosten C. In‐vitro renal epithelial cell infection
reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East
Respiratory Syndrome (MERS) Coronavirus infection. Virol J 2013; 10: 359.
11. Corman VM, Albarrak AM, Omrani AS, Albarrak MM, Farah ME, Almasri M, Muth D, Sieberg
A, Meyer B, Assiri AM, Binger T, Steinhagen K, Lattwein E, Al‐Tawfiq J, Müller MA, Drosten
C, Memish ZA. Viral shedding and antibody response in 37 patients with Middle East respiratory
syndrome coronavirus infection. Clin Infect Dis 2016; 62: 477– 83.
12. Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaarour N, Alsheikh S, Alsanouri
T. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective
investigation. East Mediterr Health J 2013; 19( Suppl. 1): S12– 8.
13. Guery B, Poissy J, el Mansouf L, Séjourné C, Ettahar N, Lemaire X, Vuotto F, Goffard A, Behillil
S, Enouf V, Caro V, Mailles A, Che D, Manuguerra JC, Mathieu D, Fontanet A, van der Werf S, MERS‐
CoV study group. Clinical features and viral diagnosis of two cases of infection with Middle East
Respiratory Syndrome coronavirus: a report of nosocomial ransmission. Lancet 2013; 381: 2265– 72.
14. Memish ZA, Zumla AI, Al‐Hakeem RF, Al‐Rabeeah AA, Stephens GM. Family cluster of Middle East
respiratory syndrome coronavirus infections. N Engl J Med 2013; 368: 2487– 94.
15. Al‐Tawfiq JA, Memish ZA. Managing MERS‐CoV in the healthcare setting. Hosp Pract
(1995) 2015; 43: 158– 63.
16. Wong RSM, Wu A, To KF, Lee N, Lam CWK, Wong CK, Chan PK, Ng MH, Yu LM, Hui DS, Tam
JS, Cheng G, Sung JJ. Haematological manifestations in patients with severe acute respiratory
syndrome: retrospective analysis. BMJ 2003; 326: 1358– 62.
17. Zucker‐Franklin D. The effect of viral infections on platelets and megakaryocytes. Semin
Hematol 1994; 31: 329– 37.
18. Leung GM, Hedley AJ, Ho L‐M, Chau P, Wong IOL, Thach TQ, Ghani AC, Donnelly CA, Fraser
C, Riley S, Ferguson NM, Anderson RM, Tsang T, Leung PY, Wong V, Chan JC, Tsui E, Lo SV, Lam
TH. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an
analysis of all 1755 patients. Ann Intern Med 2004; 141: 662– 73.
19. Hui DSC, Chan PKS. Severe acute respiratory syndrome and coronavirus. Infect Dis Clin North
Am 2010; 24: 619– 38.
20. Fan CK, Yieh KM, Peng MY, Lin JC, Wang NC, Chang FY. Clinical and laboratory features in the
early stage of severe acute respiratory syndrome. J Microbiol Immunol Infect 2006; 39: 45– 53.
21. Regueiro‐Mira MV, Pita‐Fernández S, Pértega‐Díaz S, López‐Calviño B, Seoane‐Pillado
T, Fernández‐Albalat‐Ruiz M. Prognostic factors in adult patients hospitalized for pneumonia caused
by Legionella pneumophila. Rev Chil Infectol 2015; 32: 435– 44.
22. Kawamata R, Yokoyama K, Sato M, Goto M, Nozaki Y, Takagi T, Kumagai H, Yamagata T. Utility of
serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma
pneumoniae pneumonia. J Infect Chemother 2015; 21: 783– 9.
23. Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate dehydrogenase as a biomarker for prediction of
refractory Mycoplasma pneumoniae pneumonia in children. Respir Care 2015; 60: 1469– 75.
